A
Aharon Lubetsky
Researcher at Tel Aviv University
Publications - 13
Citations - 366
Aharon Lubetsky is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Thrombophilia & Obstetrics and gynaecology. The author has an hindex of 7, co-authored 13 publications receiving 335 citations. Previous affiliations of Aharon Lubetsky include Sheba Medical Center.
Papers
More filters
Journal ArticleDOI
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance
Ronen Loebstein,Ilana Dvoskin,Hillel Halkin,Hillel Halkin,Manuela Vecsler,Aharon Lubetsky,Aharon Lubetsky,Gideon Rechavi,Ninette Amariglio,Ninette Amariglio,Yoram Cohen,Yoram Cohen,Gie Ken-Dror,Shlomo Almog,Shlomo Almog,Eva Gak +15 more
TL;DR: It is suggested that Asp36Tyr is a new marker of the high end of the warfarin dosing range and was common in Jewish ethnic groups of Ethiopian and Ashkenazi origin.
Journal ArticleDOI
Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients.
Gili Kenet,Aharon Lubetsky,B. Shenkman,I. Tamarin,R. Dardik,Gideon Rechavi,Asher Barzilai,U. Martinowitz,N. Savion,David Varon,David Varon +10 more
TL;DR: The risk of bleeding among thrombocytopenic patients with ITP, post chemotherapy and others was evaluated using the new cone and platelet analyser (CPA) test.
Journal ArticleDOI
Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome.
Yvonne Schwammenthal,Rakefet Tsabari,Boris Shenkman,Roseline Schwartz,S Matetzky,Aharon Lubetsky,David Orion,Simon Israeli-Korn,Joab Chapman,N. Savion,David Varon,David Tanne +11 more
TL;DR: Impaired responsiveness to ASA in acute brain ischaemia is common and is associated with worse neurological deficits at stroke onset, early clinical deterioration and poorer functional outcome.
Journal ArticleDOI
Platelets but not monocytes contribute to the plasma levels of factor XIII subunit A in patients undergoing autologous peripheral blood stem cell transplantation.
TL;DR: Results suggest that in the ASCT model, following myeloablation, platelets but not monocytes are the haematopoietic cells that contribute significantly to plasma FXIII A levels.
Journal ArticleDOI
Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII.
TL;DR: Both protocols appeared similar with respect to the proportion of patients responding to therapy; however, the augmented dose protocol appeared to be superior to the regular dose protocol with shorter response time, shorter duration of therapy and possibly lower rFVIIa requirements.